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ORIGINAL ARTICLE
Extension Study of PF-05280586, a Potential
Rituximab Biosimilar, Versus Rituximab in
Subjects With Active Rheumatoid Arthritis
STANLEY B. COHEN,1 RUBEN BURGOS-VARGAS,2 PAUL EMERY,3 BO JIN,4 CAROL CRONENBERGER,5
AND MARIA-DOLORES VAZQUEZ-ABAD4
Objective. This extension study provided continued treatment to subjects with active rheumatoid arthritis who had par-
ticipated for ≥16 weeks in a pharmacokinetic similarity study of PF-05280586 (potential rituximab biosimilar). Objectives
were to evaluate overall pharmacokinetics, pharmacodynamics, immunogenicity, safety, and tolerability of PF-05280586
after transition from rituximab reference products to PF-05280586, and follow-up of biomarker and efficacy assessments.
Methods. Subjects were offered ≤3 additional courses of treatment of PF-05280586, with or without a single transition
from rituximab in Europe (rituximab-EU; MabThera) or the US (rituximab-US; Rituxan) to PF-05280586. Each course
comprised 2 intravenous infusions (1,000 mg on days 1 and 15, separated by 24 weeks [ 8 weeks]).
Results. Of 220 subjects in the parent study, 185 were randomized and included in this study. There were no notable dif-
ferences in drug concentrations between groups or across courses, with little variation in depletion of CD19+ B cells
between groups, and no apparent relationship between infusion-related reactions and antidrug antibodies with or with-
out single transition from rituximab reference products to PF-05280586. Long-term safety and tolerability of PF-05280586
was acceptable in all groups for up to 96 weeks, with a low incidence of treatment-emergent adverse events independent
of single drug transition. The percentage of subjects with a low disease activity score and disease activity score remission
was similar across groups for all time points, and responses were sustained until end of study.
Conclusion. This study demonstrated acceptable safety, tolerability, and immunogenicity, with or without single tran-
sition from rituximab reference products to PF-05280586, without increased immunogenicity on single transition.
INTRODUCTION
Rituximab is a genetically engineered chimeric mouse/
human monoclonal immunoglobulin G1j antibody directed
against the CD20 antigen of B cells and is licensed under the
trade names of MabThera (Hoffman-La Roche) in Europe
(rituximab-EU) (1) and Rituxan (Genentech) in the US (ritux-
imab-US) (2). In combination with methotrexate, rituximab-
EU and -US are approved for the treatment of rheumatoid
arthritis (RA), among other diseases (1,2).
Biologics are products of genetically engineered living
cells and cannot be identical to one another (3). With the
expiration of the exclusivity of licensed or approved bio-
logic drugs, recent years have seen the approval of biosimi-
lar products that provide increased access to high-quality
established biologic therapies (4,5). While there is an expi-
ration to the patent protection of the primary sequence of
biologics, the cell lines remain proprietary, and to develop
the same biologic is not possible since a different cell line
must be used to produce a biologic product that is “highly
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similar” to the approved reference biologic (4,5). The regu-
latory agencies provide clear guidelines that define the evi-
dence needed to establish similarity between the reference
biologic and a biosimilar (4,5).
PF-05280586 is under development as a potential biosim-
ilar of rituximab, with an identical primary amino acid
sequence to rituximab; it was demonstrated to be highly
similar based on comparison of physicochemical critical
attributes, and nonclinical and in vitro functional charac-
teristics (6). In a randomized 3-way pharmacokinetic (PK)
similarity study in subjects with active RA, PK equivalence
was demonstrated between PF-05280586 and rituximab-
EU, PF-05280586 and rituximab-US, and rituximab-EU and
rituximab-US. This study also demonstrated comparable
CD19+ B cell depletion, pharmacodynamic (PD) responses,
safety, and immunogenicity profiles for all treatments (7).
This extension study was designed to provide contin-
ued access up to an additional 3 courses of treatment
with PF-05280586, with or without a single transition
(either at course 1 or course 2) from rituximab-EU or
rituximab-US to PF-05280586 in subjects with active RA
who fulfilled entry criteria. This article reports the PK,
PD, immunogenicity, safety, and clinical data of the
extension study, which include blinded randomization
with or without single transition from rituximab refer-
ence products to PF-05280586, for this cohort of subjects
with active RA. Since the study was not designed for a
formal statistical analysis of PK, PD, immunogenicity,
safety, and efficacy end points, the data are presented
with descriptive statistics.
SUBJECTS AND METHODS
Study design. This study was an extension offered to
subjects with active RA who had participated in the ran-
domized, parallel-group, 3-arm clinical PK study for at least
16 weeks, up to 2 months after completion of the parent
study and who had not received intervening treatment with
investigational agents or other biologics (including rituximab-
EU or rituximab-US). The parent study included subjects
with active RA who were randomized (1:1:1) to receive
PF-05280586, rituximab-EU, or rituximab-US, each admin-
istered as 2 intravenous (IV) 1,000-mg doses on study days 1
and 15, and has been previously published (7).
This extension study was conducted at 48 centers in 10
countries in compliance with the provisions of the Declara-
tion of Helsinki and in accordance with international stan-
dards of good clinical practice. All subjects provided
informed consent prior to undergoing any screening proce-
dures. The final protocol, amendments, and informed con-
sent documentation were reviewed and approved by an
institutional review board or independent ethics committee
at each of the participating investigational sites. The study
was supported by Pfizer and registered at ClinicalTrials.gov
(NCT01643928).
Study population. This study was conducted in subjects
with active RA who received background therapy with
methotrexate, and had an inadequate response to at least 1
tumor necrosis factor antagonist therapy when they entered
the parent study. In addition to the criteria related to their
participation in the parent study, subjects were excluded
from the extension study if they required treatment with
prohibited concomitant medications during the study,
including live attenuated vaccines, cytotoxic drugs, predni-
sone >10 mg/day or equivalent, disease-modifying antirheu-
matic drugs (other than stable dose of methotrexate up to 25
mg weekly), plasma exchange therapy, or immunoglobulin.
Subjects were also excluded from the study if they
had a severe reaction to rituximab reference products or
PF-05280586, or a serious adverse event (SAE) that was
deemed to be related to the study drug in the parent study.
Subjects with an absolute neutrophil count ≤1,500 cells/mm3
or immunoglobulin G levels <300 mg/dl were also excluded
from the study.
Treatments. All subjects were offered up to 3 courses of
study treatment. Each course was divided into 2 IV infusions
of 1,000 mg of study treatment administered on days 1 and
15, and separated from the next course by 24 weeks ( 8
weeks). The first course of this extension study randomized
subjects as follows: those who received rituximab-EU in the
parent study were blindly randomized (1:1) to either con-
tinue on rituximab-EU (E-E) or receive PF-05280586 (E-P),
and subjects who received rituximab-US were blindly
randomized (1:1) to either continue rituximab-US (U-U) or
receive PF-05280586 (U-P). All subjects who continued after
the end of course 1 received PF-05280586 for courses 2 and
3 in this study (E-EPP and E-PPP, or U-UPP and U-PPP,
respectively). Subjects who received PF-05280586 in the
parent study continued blind randomization to receive
PF-05280586 for courses 1, 2, and 3 (P-P, P-PP, P-PPP, re-
spectively) (Figure 1). Study treatments were administered
in accordance with health authority–approved product labels
for RA.
Objectives. This study was designed to provide continued
treatment access to subjects with active RA who had
participated for at least 16 weeks in the parent study. In
addition, the objectives of this study were to evaluate the
overall PK, PD, immunogenicity, safety, and tolerability of
Significance & Innovations
• This is the first disclosure of the results of the clini-
cal extension study of PF-05280586 (a proposed
biosimilar) versus rituximab reference products
sourced in the European Union (MabThera,
Hoffman-LaRoche) and the US (Rituxan, Genentech)
in subjects with active rheumatoid arthritis who had
participated in a PF-05280586 pharmacokinetic
equivalence study.
• The results provide evidence of comparability of
pharmacokinetics, pharmacodynamics, immuno-
genicity, and safety of PF-05280586, with or without
single transition from rituximab reference products,
and show no increased immunogenicity on single
transition to PF-05280586.
PF-05280586: A Potential Biosimilar to Rituximab 1599
PF-05280586 after transition from a rituximab reference
product to PF-05280586, and to continue follow-up of
biomarker and efficacy end points of interest in the parent
study.
Pharmacokinetics. Blood samples to determine study
drug concentrations were collected prior to dosing on days
1 and 15  3 days, and then on days 85  7 and 169  7
days during each of courses 1, 2, and 3. All samples were
analyzed at QPS (Newark, DE) using a validated, single
enzyme-linked immunosorbent assay to quantitatively
measure total concentrations of PF-05280586, rituximab-
EU, and rituximab-US in human serum.
Immunogenicity. Serum samples for the determination of
antidrug antibodies (ADA) were collected concurrently with
PK samples and tested using 2 validated assays. Serum sam-
ples from subjects who received PF-05280586 in the parent
study were screened for ADA using the assay specific to
PF-05280586, and if confirmed positive, samples were also
analyzed using the assay specific for the rituximab reference
products to assess cross-reactivity of the ADA. Serum sam-
ples from subjects who received rituximab reference prod-
ucts in the parent study were screened for ADA using both
assays (PF-05280586 and rituximab reference products) to
assess any product-specific ADA and/or cross-reactivity,
since these subjects were exposed to the rituximab reference
products followed by PF-05280586.
Blood samples that were confirmed positive for ADA
were further titered and tested for neutralizing antibodies
(nAbs). Samples that were confirmed positive for nAbs were
also titered. An electrochemiluminescence immunoassay
was used for detection of ADAs, while nAbs were detected
using a cell-based assay, in accordance with relevant regula-
tory guidance (4,5).
Safety. Safety evaluations included clinical assessments,
vital signs, 12-lead electrocardiograms, adverse events (AEs),
and safety laboratory tests. AEs and laboratory abnormalities
were characterized by their type, incidence, severity, timing,
seriousness, and relatedness to drug treatment. The severity
of AEs was graded in accordance with the National Cancer
Institute Common Terminology Criteria for Adverse Events,
version 4.03.
Efficacy. Although this study was not designed for a
formal analysis of efficacy, disease activity was assessed
by the percentage of subjects achieving low disease
activity score (DAS ≤3.2, using the 28-joint count) and
DAS remission rate (<2.6) per treatment group over time.
Efficacy parameters were assessed on weeks 1, 6, 13,
and 25 of each course, with a follow-up on weeks 24 and
48 after the final day of the last course of treatment. As
the time between courses could range from 16 to 32
weeks after the first day of dosing of the previous course
of treatment, some subjects entered the next course
before week 25 of that course. Here, we report assess-
ments of all courses at weeks 1 and 13, and also at week
25 of course 3.
Statistical analysis. No formal hypothesis or statistical
inferences were evaluated in this study. Descriptive sta-
tistics were presented for study disposition, demographics,
PK, immunogenicity, safety, and efficacy data. The intent-
to-treat (ITT) population was defined as all subjects who
were randomized to the study treatment, and was primarily
used for subject accountability. Subjects’ disposition,
demographics, and baseline characteristics were summa-
rized based on the ITT population. The modified ITT
(mITT) population was defined as all subjects who were
randomized and received at least 1 dose of study treatment.
Figure 1. Study design. E-E, E-EP, E-EPP = subjects who were randomized to the rituximab-Europe (EU) cohort in the parent study and
then randomized in this study to receive the rituximab-EU reference product during course 1, followed by the PF-05280586 investiga-
tional product during courses 2 and 3; E-P, E-PP, E-PPP = subjects who were randomized to the rituximab-EU cohort in the parent
study and then randomized in this study to receive the PF-05280586 investigational product during courses 1, 2 and 3; U-P, U-PP,
U-PPP = subjects who were randomized to rituximab-US in the parent study and then randomized in this study to receive the
PF-05280586 investigational product during courses 1, 2 and 3; U-U, U-UP, U-UPP = subjects who were randomized to rituximab-US in
the parent study and then randomized in this study to receive the US reference product during course 1, followed by the PF-05280586
investigational product during courses 2 and 3; P-P, P-PP, P-PPP = subjects who were randomized to PF-05280586 in the parent study
and continued receiving the PF-05280586 investigational product in this study during courses 1, 2 and 3; MTX = methotrexate.
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The evaluations for PK, immunogenicity, safety, and
efficacy data were conducted on the mITT population.
RESULTS
Subject demographics and disposition. Of the 220 sub-
jects treated in the parent study, 35 did not meet the
inclusion criteria for the extension study; therefore, 185
subjects were randomized and included in the ITT popu-
lation in this study (see Supplementary Figure 1, available on
the Arthritis Care & Research web site at http://onlinelibrary.
wiley.com/doi/10.1002/acr.23586/abstract). Of these 185 sub-
jects, 59 received PF-05280586 in the parent study and
remained on PF-05280586 in this study, 66 received rituximab-
EU in the parent study and were blindly randomized 1:1 to
continued rituximab-EU or PF-05280586 in this study, and 60
who received rituximab-US in the parent study were blindly
randomized 1:1 to either continued rituximab-US or PF-
05280586 in this study (Figure 1). All subjects who continued
after the end of course 1 received PF-05280586 for courses 2
and 3 in this study. Six subjects in the P-PPP group, and 1
subject each in the E-EPP and E-PPP groups discontinued
treatment. There were no treatment discontinuations in
the U-UPP or U-PPP groups. Baseline demographics were
similar across treatment groups (Table 1).
Study drug concentrations. During course 1, the geo-
metric mean (coefficient of variation) concentrations of
study drug increased from 10.9 ng/ml (232.5%) at week 1 to
a maximum of 97,537.6 ng/ml (30.5%) at week 3. This was
followed by a slow decline to 594.7 ng/ml (162.6%) at week
25. Similar trends were noted during courses 2 and 3.
There were no notable differences in drug concentrations
between treatment groups or across treatment courses.
In general, the appearance of ADA resulted in a slight
decrease in drug concentrations; however, this observa-
tion should be interpreted with caution given the rela-
tively small numbers of subjects who were ADA+. None
of the samples that tested positive for ADAs tested posi-
tive for neutralizing activity in this study.
Pharmacodynamics. Depletion of CD19+ B cells from
treatment in the parent study was seen at the time of
Table 1. Demographic and baseline characteristics by treatment sequence (ITT population)*
Characteristic
PS: PF-05280586,
ES: PPP
(n = 59)†
PS: rituximab-EU PS: rituximab-US
Total
(n = 185)
ES: EPP
(n = 33)
ES: PPP
(n = 33)‡
ES: UPP
(n = 30)
ES: PPP
(n = 30)§
Age, years¶
No. 59 33 33 30 30 185
Mean  SD 55.4  1.91 56.3  1.82 56.7  9.35 52.6  3.73 55.8  0.35 55.4  11.51
Range 29–80 30–75 40–74 26–81 34–82 26–82
Sex, no. (%)
Male 9 (15.3) 3 (9.1) 10 (30.3) 10 (33.3) 5 (16.7) 37 (20.0)
Female 50 (84.7) 30 (90.9) 23 (69.7) 20 (66.7) 25 (83.3) 148 (80.0)
Race, no. (%)
White 44 (74.6) 23 (69.7) 26 (78.8) 25 (83.3) 21 (70.0) 139 (75.1)
Black 1 (1.7) 3 (9.1) 3 (9.1) 3 (10.0) 2 (6.7) 12 (6.5)
Asian 3 (5.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (1.6)
Other 11 (18.6) 7 (21.2) 4 (12.1) 2 (6.7) 7 (23.3) 31 (16.8)
Height, cm
No. 59 32 32 29 30 182
Mean  SD 164.90  8.170 165.28  0.623 166.92  10.193 167.09  9.426 164.39  8.226 165.59  9.175
Range 147.4–188.0 145.4–190.5 143.5–188.0 148.6–185.4 150.0–188.0 143.5–190.5
Weight, kg
No. 59 33 33 30 30 185
Mean  SD 86.51  20.960 78.10  21.176 86.78  16.585 87.98  23.661 73.74  18.335 83.23  20.841
Range 41.7–127.9 43.5–121.1 54.1–122.5 49.8–133.3 45.0–128.6 41.7–133.3
BMI, kg/m2
No. 59 32 32 29 30 182
Mean  SD 31.81  7.514 28.59  6.833 31.46  5.367 30.68  6.420 27.12  5.487 30.23  6.739
Range 18.0–45.0 15.8–43.1 21.3–41.6 20.7–42.7 17.3–41.0 15.8–45.0
* ITT = intent-to-treat; PS = parent study treatment; ES = extension study treatment; EPP = subjects who were randomized to rituximab-EU
(European Union) in the parent study and then randomized in this study to receive the EU reference product during course 1, followed by the
PF-05280586 investigational product during courses 2 and 3; UPP = subjects who were randomized to rituximab-US in the parent study and then
randomized in this study to receive the US reference product during courses 1, followed by the PF-05280586 investigational product during courses
2 and 3; BMI = body mass index.
† Subjects who were randomized to PF-05280586 investigational product in the parent study and continued receiving PF-05280586 investigational
product in this study during courses 1, 2, and 3.
‡ Subjects who were randomized to rituximab-EU in the parent study and then randomized in this study to receive PF-05280586 investigational
product during courses 1, 2, and 3.
§ Subjects who were randomized to rituximab-US in the parent study and then randomized in this study to receive PF-05280586 investigational
product during courses 1, 2, and 3.
¶ Age at randomization.
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entry in this study, and showed little variation between
treatment groups after course 1.
ADA test results. ADA samples were available from
181 subjects who received at least 1 dose of study drug.
The incidence of ADA response observed in this study
during the combined courses 1–3 was 13.3% with the
anti-rituximab antibody assay and 10.0% with the anti–
PF-05280586 antibody assay.
There were 173 samples with baseline ADA test results
available. Of the 27 subjects who were ADA+ at baseline in
this study, 19 (70%) were also ADA+ in the parent study,
20 (74%) had cross-reactive ADA with similar titers, and 23
(85%) reverted to ADA– by their last visit. The remaining 4
subjects were ADA+ at their last visit. Of these, 1 subject
(randomized to the P-PPP group) had stable titers of
treatment-emergent, cross-reactive ADA+ without infusion-
related reactions (IRRs) throughout the parent study, and
entered this extension study with similar ADA titers,
reporting an IRR during course 1 that led to withdrawal
from the study. Another subject (E-PPP) had cross-reactive
ADA titers of <1.88/2.64 at entry into the extension study
and 4.87/4.58 at the follow-up visit, with no IRR. The last 2
subjects had stable titers and no IRR (E-PPP and U-UPP).
Of the 146 subjects who were ADA– at pre-dose, 1 (<1%)
had tested positive in the parent study but remained ADA–
throughout this study, despite testing positive in the parent
study. Additionally, 17 of 146 subjects (12%) became
ADA+ during this study, of which 15 of 17 (88%) were
ADA– in the parent study. Finally, 5 of 146 subjects (3.4%)
remained ADA+ at the last visit and did not report an IRR.
In total, 11 of 17 subjects (65%) who were ADA+ had cross-
reactive ADAs with similar titers.
Infusion-related reactions. Overall, 6 subjects reported
an IRR during the study that was deemed to be related to
study treatment (Table 2). Of these, 2 of 6 subjects (33.3%;
1 each in the P-PPP and U-PPP groups) were ADA–. The
remaining 4 of 6 subjects (66.7%) were ADA+, of whom 1
subject in the P-P group experienced grade 3 IRR (rash
papular) and was ADA+ at the same time point. This
subject was permanently discontinued from the study. Two
subjects (1 each in the U-UPP and E-PPP groups) were
ADA+ after reporting their IRRs and 1 in the P-PPP group
was ADA+ before reporting an IRR (Table 2). All IRRs
occurred at course 1 or 2, and none were reported at the
final drug exposure on course 3. None of the IRRs were
serious in nature and all were resolved.
Safety results. Among subjects who received course 1
treatment, 90 of 183 subjects (49.2%) experienced at least 1
treatment-emergent adverse event (TEAE) by the end of
course 1. Of those who received treatment courses 1 and 2,
115 of 173 subjects (66.5%) experienced TEAEs by the end of
course 2. Among those who received 3 courses of treatment,
119 of 164 subjects (72.6%) experienced TEAEs by the end of
course 3 (Table 3). The most frequent TEAEs (occurring in at
least 5 subjects) were from the system organ class of
infections and infestations (Table 4). The most frequent and
common single TEAE was worsening of the subject’s RA.
TEAEs led to withdrawals from study treatment in 3 of 183
subjects (3.4%) by the end of course 1 (1 subject each in the
P-P, E-E, and U-P groups), 3 of 173 (1.8%) by the end of
course 2 (1 in the P-PP and 2 in the U-UP groups), and 1 of
164 (0.4%) by the end of course 3 (U-PPP group). There were
no dose reductions due to AEs during this study.
By the end of course 3, 46 of 164 subjects (28.0%) reported
treatment-related AEs: 12 of 48 (25.0%), 5 of 30 (16.7%), 11
of 30 (36.7%), 11 of 27 (40.7%), and 7 of 29 subjects (24.1%)
in the P-PPP, E-EPP, E-PPP, U-UPP, and U-PPP groups,
respectively. The most frequent treatment-related AEs across
all treatment groups were infections, reported as sinusitis in
7, bronchitis in 6, upper respiratory tract infection in 5, and
oral herpes in 3 subjects. In addition, cough was reported
in 4 subjects, and decreased white blood cell count and
headache in 3 subjects each.
Table 3. Treatment-emergent adverse events (TEAEs; all causalities) by treatment sequence in subjects who received courses
1, 2, and 3 (modified intent-to-treat population)*
Subjects
PS: PF-05280586,
ES: PPP
(n = 48)†
PS: Rituximab-EU PS: Rituximab-US
Total
(n = 164)
ES: EPP
(n = 30)
ES: PPP
(n = 30)‡
ES: UPP
(n = 27)
ES: PPP
(n = 29)§
Any TEAE 34 (70.8) 21 (70.0) 23 (76.7) 20 (74.1) 21 (72.4) 119 (72.6)
Serious TEAE 4 (8.3) 1 (3.3) 4 (13.3) 1 (3.7) 1 (3.4) 11 (6.7)
TEAE resulting in withdrawal from study treatment 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.4) 1 (0.6)
TEAE resulting in withdrawal from study 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.4) 1 (0.6)
Treatment-related TEAE 12 (25.0) 5 (16.7) 11 (36.7) 11 (40.7) 7 (24.1) 46 (28.0)
TEAE grade ≥3 5 (10.4) 2 (6.7) 7 (23.3) 2 (7.4) 3 (10.3) 19 (11.6)
* Values are the number (percentage). PS = parent study treatment; ES = extended study treatment; EU = European Union; EPP = subjects who were
randomized to rituximab-EU in the parent study and then randomized in this study to receive the EU reference product during course 1, followed
by the PF-05280586 investigational product during courses 2 and 3; UPP = subjects who were randomized to rituximab-US in the parent study and
then randomized in this study to receive the US reference product during course 1, followed by the PF-05280586 investigational product during
courses 2 and 3.
† Subjects who were randomized to PF-05280586 investigational product in the parent study and continued receiving PF-05280586 investigational
product in this study during courses 1, 2, and 3.
‡ Subjects who were randomized to rituximab-EU in the parent study and then randomized in this study to receive PF-05280586 investigational
product during courses 1, 2, and 3.
§ Subjects who were randomized to rituximab-US in the parent study and then randomized in this study to receive PF-05280586 investigational
product during courses 1, 2, and 3.
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SAEs were reported in 11 of 183 subjects (6.0%) dur-
ing course 1, 14 of 173 (8.1%) by the end of course 2,
and in 11 of 164 subjects (6.7%) by the end of course 3.
There were no observed clinically meaningful differ-
ences in the incidence of SAEs across treatment groups.
Pneumonia was the most frequently reported SAE in 3
of 164 subjects (1.8%; 1 of 48 [1.4%] in the P-PPP group
and 2 of 30 subjects [4.5%] in the E-PPP group). Three
subjects reported 3 SAEs (pericarditis [E-PPP], infec-
tious arthritis [P-PPP], and wound staphylococcal infec-
tion [E-PPP]) that were deemed to be treatment related.
No cases of progressive multifocal leukoencephalopathy
(an event of special interest) were reported during the
study.
There were no deaths in this study. There were no
observed clinically meaningful changes in laboratory
parameters or vital signs, and no observed clinically
meaningful differences among the treatment groups.
Efficacy results. Low DAS rate (≤3.2). This study re-
ports efficacy measures independent from baseline. The
overall low DAS rate in subjects who received course 1 of
treatment was 23.3% at week 1. The overall lowDAS rate was
53.1% at course 1, week 13. For subjects who received course
1 and course 2 treatments, the overall low DAS rate was
55.7% at course 2, week 13. All groups showed similar low
DAS rates after 3 courses of treatment (Figure 2A). The overall
lowDAS response ratewas 50.9%at the end of treatment.
DAS remission rate (<2.6). The overall DAS remission
rate was 37.9% at course 1, week 13. For subjects who
received both course 1 and course 2 treatments, the overall
DAS remission rate was 35.3% at course 2, week 13. For
subjects who received 3 courses of treatment, all groups
showed similar DAS remission rates over time (Figure 2B).
The overall DAS remission rate was 42.1% at week 13,
course 3. The overall DAS remission rate was 36.6% at the
end of treatment.
Table 4. Treatment-emergent adverse events (all causalities) in at least 5 subjects who received courses 1, 2, and 3
(modified intent-to-treat population)*
Events
PS: PF-05280586,
ES: PPP
(n = 48)†
PS: Rituximab-EU PS: PF-05280586
Total
(n = 164)
ES: EPP
(n = 30)
ES: PPP
(n = 30)‡
ES: UPP
(n = 27)
ES: PPP
(n = 29)§
Any AE 34 (48.8) 21 (50.1) 23 (52.3) 20 (53.4) 21 (50.2) 119 (50.7)
Blood and lymphatic disorders 3 (4.3) 0 (0.0) 2 (4.5) 1 (2.7) 1 (2.4) 7 (3.0)
Eye disorders 0 (0.0) 1 (2.4) 2 (4.5) 2 (5.3) 0 (0.0) 5 (2.1)
Gastrointestinal disorders 6 (8.6) 6 (14.3) 4 (9.1) 6 (16.0) 4 (9.6) 26 (11.1)
Diarrhea 1 (1.4) 1 (2.4) 1 (2.3) 3 (8.0) 2 (4.8) 8 (3.4)
Nausea 3 (4.3) 0 (0.0) 1 (2.3) 1 (2.7) 2 (4.8) 7 (3.0)
Vomiting 2 (2.9) 1 (2.4) 2 (4.5) 1 (2.7) 1 (2.4) 7 (3.0)
General disorders and administration site conditions 6 (8.6) 6 (14.3) 2 (4.5) 4 (10.7) 2 (4.8) 20 (8.5)
Edema peripheral 1 (1.4) 2 (4.8) 1 (2.3) 3 (8.0) 0 (0.0) 7 (3.0)
Infections and infestations 23 (33.0) 13 (31.0) 12 (27.3) 9 (24.0) 16 (38.2) 73 (31.1)
Bronchitis 5 (7.2) 2 (4.8) 2 (4.5) 3 (8.0) 2 (4.8) 14 (6.0)
Upper respiratory tract infection 2 (2.9) 4 (9.5) 1 (2.3) 4 (10.7) 3 (7.2) 14 (6.0)
Sinusitis 4 (5.7) 2 (4.8) 3 (6.8) 2 (5.3) 2 (4.8) 13 (5.5)
Urinary tract infection 5 (7.2) 1 (2.4) 3 (6.8) 1 (2.7) 2 (4.8) 12 (5.1)
Nasopharyngitis 1 (1.4) 0 (0.0) 1 (2.3) 1 (2.7) 2 (4.8) 5 (2.1)
Injury, poisoning, and procedural complications 6 (8.6) 6 (14.3) 8 (18.2) 4 (10.7) 5 (12.0) 29 (12.3)
Fall 1 (1.4) 3 (7.2) 2 (4.5) 1 (2.7) 0 (0.0) 7 (3.0)
Investigations 4 (5.7) 3 (7.2) 2 (4.5) 3 (8.0) 2 (4.8) 14 (6.0)
Metabolism and nutrition disorders 3 (4.3) 2 (4.8) 4 (9.1) 6 (16.0) 3 (7.2) 18 (7.7)
Musculoskeletal and connective tissue disorders 15 (21.5) 5 (11.9) 9 (20.4) 6 (16.0) 8 (19.1) 43 (18.3)
Arthralgia 1 (1.4) 1 (2.4) 2 (4.5) 2 (5.3) 0 (0.0) 6 (2.6)
Back pain 2 (2.9) 0 (0.0) 2 (4.5) 2 (5.3) 0 (0.0) 6 (2.6)
Rheumatoid arthritis 5 (7.2) 3 (7.2) 3 (6.8) 2 (5.3) 2 (4.8) 15 (6.4)
Neoplasms (benign/malignant/unspecified/cysts/polyps) 2 (2.9) 0 (0.0) 2 (4.5) 2 (5.3) 0 (0.0) 6 (2.6)
Nervous system disorders 4 (5.7) 1 (2.4) 6 (13.6) 4 (10.7) 2 (4.8) 17 (7.2)
Headache 1 (1.4) 0 (0.0) 2 (4.5) 1 (2.7) 1 (2.4) 5 (2.1)
Dizziness 2 (2.9) 1 (2.4) 1 (2.3) 1 (2.7) 1 (2.4) 6 (2.6)
* Values are the number (percentage). PS = parent study treatment; ES = extended study treatment; EU = European Union; EPP = subjects who were
randomized to rituximab-EU in the parent study and then randomized in this study to receive the EU reference product during course 1, followed
by the PF-05280586 investigational product during courses 2 and 3; UPP = subjects who were randomized to rituximab-US in the parent study and
then randomized in this study to receive the US reference product during course 1, followed by the PF-05280586 investigational product during
courses 2 and 3.
† Subjects who were randomized to PF-05280586 investigational product in the parent study and continued receiving PF-05280586 investigational
product in this study during courses 1, 2 and 3.
‡ Subjects who were randomized to rituximab-EU in the parent study and then randomized in this study to receive PF-05280586 investigational
product during courses 1, 2, and 3.
§ Subjects who were randomized to rituximab-US in the parent study and then randomized in this study to receive PF-05280586 investigational
product during courses 1, 2, and 3.
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DISCUSSION
As patent protection and data exclusivity for rituximab
expire, potential rituximab biosimilars are in development.
Indeed, CT-P10, a biosimilar version of rituximab, is ap-
proved in South Korea (8) and Europe (9) for the treatment
of RA, chronic lymphocytic leukemia (CLL), and non-
Hodgkin’s lymphoma (NHL). Another rituximab biosimilar,
L01XC02, is approved in Europe for the treatment of NHL,
CLL, RA, granulomatosis with polyangiitis, and microscopic
polyangiitis (also approved under a duplicate marketing
authorization for the treatment of NHL, RA, granulomatosis
with polyangiitis, and microscopic polyangiitis) (9). The
availability of rituximab biosimilars may increase patient
access to safe and efficacious medicines (10).
This study provided continued treatment access to a
small cohort of subjects with active RA who had partici-
pated in the parent study of a rituximab biosimilar (7). In
this extension study, subjects were offered up to 3 addi-
tional courses of treatment, with or without a single transi-
tion from rituximab reference products to PF-05280586.
Although the number of subjects who discontinued treat-
ment in the P-PPP arm was numerically higher than in the
other treatment groups, this was not considered clinically
relevant. Similar drug concentrations were observed across
treatment groups in this study. All treatment groups
showed complete and sustained depletion of CD19+ B cells.
The incidence of ADA response observed in this study
during the combined courses 1–3 was consistent with the
published incidence of ADA: 11% in subjects with RA
treated with rituximab in long-term studies (2). There was
no apparent time relationship between IRR reports and
ADA+ with or without single transition from rituximab ref-
erence products to PF-05280586 in this study. In total, 6
subjects experienced an IRR during this study that was
deemed to be related to study treatment. However, no con-
sistent trends were observed between IRRs after single tran-
sition from rituximab reference products to PF-05280586.
Moreover, IRRs occurred at courses 1 or 2, and none were
noted at course 3 during the last drug re-challenge.
The long-term safety and tolerability of PF-05280586
was acceptable in all groups up to 96 weeks in this
extension study, with a low incidence of TEAEs or dis-
continuations due to AEs, independent of single transi-
tion from rituximab reference products to PF-05280586.
The pattern and frequency of SAEs, incidence of IRRs,
grade ≥3 TEAEs, and withdrawal of subjects due to AEs
were similar across the treatment groups. The percent-
age of subjects with low DAS and DAS remission were
similar across the treatment groups for all time points,
and the responses were sustained until the end of the
study.
In conclusion, this study demonstrated tolerability and
acceptable safety with or without single transition from
rituximab reference products to PF-05280586, and did not
demonstrate increased immunogenicity on re-challenge or
single transition based on either ADA or IRR reports. These
data support the continued development of PF-05280586 as
a potential biosimilar to rituximab. A randomized compara-
tive clinical study evaluating efficacy, safety, PK, and
immunogenicity of PF-05280586 and rituximab-EU mono-
therapy in treatment-naive subjects with CD20+ low tumor
burden follicular lymphoma is ongoing (ClinicalTrials.gov
NCT02213263).
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Figure 2. A, Low Disease Activity Score (DAS; ≤3.2) rate by treatment sequence and visit (modified intent-to-treat population [mITT]);
n = proportion of subjects with low DAS (≤3.2) for each treatment sequence and visit. B, DAS remission (<2.6) rate by treatment
sequence and visit (mITT population); n = proportion of subjects with DAS remission (<2.6) for each treatment sequence and visit. N =
total number of subjects receiving treatment in each course/week. See Figure 1 for randomized study group descriptions.
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